The fertility testing market offers a variety of ovulation prediction kits and fertility monitors to help women track their ovulation cycles and fertile window. Ovulation prediction kits detect the LH levels in urine which surge just before ovulation while fertility monitors track various fertility biomarkers such as estrogen, LH levels, and basal body temperature using advanced algorithms to more accurately predict ovulation. There is a growing dependence on these products for planning and achieving pregnancy among women with irregular or unpredictable periods and those wanting to boost their fertility naturally.
The global fertility testing market is estimated to be valued at US$ 667.13 Mn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in The Fertility Testing Market are AstraZeneca, Novartis AG, GSP plc, Merck & Co., Inc., Verona Pharma plc, Regeneron Pharmaceuticals Inc., and Boehringer Ingelheim International GmbH. These players are focusing on launching innovative and clinically-validated products to strengthen their market position.
There is high demand for convenient and affordable home use fertility tests which is fueling product innovations. Digitalization of fertility tracking using mobile apps integrated with trackers and kits is also gaining traction.
Asia Pacific and Middle East regions are witnessing growing commercialization of fertility management products driven by rising first-time pregnancy age and lifestyle changes. Major players are expanding their presence in emerging countries through strategic collaborations.
Market Drivers
The average age of first-time mothers has been consistently rising globally. Delayed parenthood owing to social-economic factors is prompting more women to proactively plan and boost their fertility naturally. This is a major driver for the increased adoption of ovulation prediction kits and fertility monitors. According to the National Centre for Health Statistics, the mean age of first-time mothers in the US rose from 24.9 years in 2000 to 26.3 years in 2014.
PEST Analysis
Political: Fertility testing market is regulated by healthcare authorities like FDA in US and EMA in Europe. Regulations determine the approval process and ensure safety and efficacy of products.
Economic: Recovering global economy and rising incomes are increasing healthcare spending. This is positively impacting demand for fertility testing products. However, pricing pressures may limit premiumization.
Social: Delayed marriages and rising age of first-time motherhood are leading to infertility issues. Growing social acceptance of IVF and other assisted reproductive technologies is driving the use of fertility testing.
Technological: Advanced technologies like next-gen sequencing, AI/ML applications, mobile-based solutions, and digital diagnostics are improving accuracy, convenience and driving innovation in fertility testing. Wearables and home use products are gaining popularity.
Geographical regions with high market concentration
North America accounts for the largest share of the global fertility testing market due to factors like favourable reimbursement policies, technological advancements, and increasing awareness about fertility testing. The US dominates the North American as well as global fertility testing market.
Fastest growing region
Asia Pacific region is expected to grow at the fastest pace during the forecast period due to rising infertility rates, increasing healthcare expenditures, growing middle-class population, and increasing awareness about fertility and infertility treatment options. China and India are the major contributors to the fertility testing market growth in Asia Pacific.
